Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Forbo Holding AG    FORN   CH0003541510

FORBO HOLDING AG

(FORN)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Gilead Sciences snares Roche veteran O'Day as CEO

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/10/2018 | 05:00am EST
FILE PHOTO: Roche Pharmaceuticals CEO O'Day attends a news conference in Basel

(Reuters) - Drugmaker Gilead Sciences Inc on Monday named Roche Holding AG's Daniel O'Day as its new chief executive, tapping an industry veteran to fill a management vacuum.

O'Day, now head of Roche's pharmaceuticals business, joined the company in 1987 and held various roles in the United States before moving in 1998 to headquarters in Basel, Switzerland.

O'Day's hiring comes about four months after Gilead said in July that Chief Executive John Milligan and Chairman John Martin would step down at the end of the year.

Jefferies analysts said in a note that O'Day's three decades of oncology and global commercial expertise at Roche should help Gilead build out its own global presence, particularly in new areas it is entering including oncology and inflammation as well as through more acquisitions and in-licensing deals.

At Roche, O'Day was a champion of bi-specific antibodies that are under development as a potentially less expensive, less complicated alternative to CAR-T therapy where T cells must be taken out of the body, re-engineered and re-infused.

With Gilead's Yescarta therapy, O'Day is now on the opposite side of the divide.

Separately, Roche said William Anderson, current CEO of its Genentech business, would replace O'Day next year.

Anderson joined Roche in 2006, leading the immunology business unit in Genentech, and then took charge of oncology sales and marketing. In 2013, he became head of global product strategy based in Basel before assuming his current role at Genentech in 2017.

Vontobel analyst Stefan Schneider called Anderson a "seasoned Roche manager" who played a key role in leading multiple sclerosis drug Ocrevus to success and driving double-digit growth in the U.S. market.

Gilead said on Monday that Martin would step down from the company's board of directors, effective March 1, 2019.

Up to Friday's close, the company's shares have fallen nearly 14 percent since Milligan and Martin's departures were announced by Gilead in July.

The Wall street Journal first reported O'Day's hiring on Sunday.

Gilead said its board had appointed Gregg Alton as interim chief executive for the period of January 1, 2019 until O'Day's start date of March 1, 2019.

Roche shares were down 0.6 percent by mid-morning, in line with the Stoxx European health care sector index.

(Reporting by Liana Baker in New York; Additional reporting by Ismail Shakil and Philip George in Bengaluru and by John Miller and Michael Shields in Zurich; Editing by Sunil Nair and Mark Potter)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on FORBO HOLDING AG
07/26Media release Forbo Group on the first half-year 2019
TE
07/17Fed - Sunny outlook for U.S. despite shade thrown by trade
RE
07/17As Fed nears rate cut, policymakers debate how deep, and even if
RE
07/15Groping for new tools, central banks look at Japan's yield controls
RE
07/12GRAIN HIGHLIGHTS : Top Stories of the Day
DJ
07/11BOSTIC : Fed's focus is its mandates not market pricing for rate cuts
RE
07/11Fed's Powell affirms rate cut view; others see U.S. economy humming
RE
07/11Powell testimony, Fed meeting highlight case for 'insurance'
RE
07/11Fed's Powell, in Trump's crosshairs, gets backing from Congress
RE
07/11Powell testimony, Fed meeting highlight case for 'insurance'
RE
More news
Financials (CHF)
Sales 2019 1 269 M
EBIT 2019 174 M
Net income 2019 137 M
Finance 2019 166 M
Yield 2019 1,39%
P/E ratio 2019 18,3x
P/E ratio 2020 17,6x
EV / Sales2019 1,87x
EV / Sales2020 1,81x
Capitalization 2 544 M
Chart FORBO HOLDING AG
Duration : Period :
Forbo Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FORBO HOLDING AG
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 1 702,14  CHF
Last Close Price 1 588,00  CHF
Spread / Highest target 14,6%
Spread / Average Target 7,19%
Spread / Lowest Target -2,39%
EPS Revisions
Managers
NameTitle
Stephan Bauer Chief Executive Officer
Mathias Ernst Schneider Executive Chairman
Urs Uehlinger Chief Financial Officer
Michael Pieper Vice Chairman
Vincent Studer Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
FORBO HOLDING AG15.13%2 562
KINGSPAN GROUP24.40%9 226
TARKETT-14.10%1 103
MONALISA GROUP CO LTD--.--%955
DYNASTY CERAMIC PCL--.--%460
NORCROS PLC25.26%236